Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- Jul 16
- 1 min read
14/07/2026
Innovent Biologics and Spero Therapeutics announced an exclusive licensing agreement for IBI355 for the treatment of immune-mediated diseases (Ref)
Innovent Biologics and Spero Therapeutics announced an exclusive license agreement for IBI355 (SP001; a third-generation Fc-silent anti-CD40L antibody) for immune-mediated diseases.
Under the agreement, Spero obtained exclusive global rights, excluding Greater China to develop, research, manufacture and commercialize IBI355, while Innovent retained rights in Greater China.
Innovent was eligible to receive an upfront payment plus development, regulatory, and commercial milestone payments totaling approximately US$1.1 billion, along with tiered royalties on net sales.
Spero planned to initiate a Phase 2 trial for IBI355 in Q2 2027 in IgG4-related disease.
Innovent planned to initiate a Phase 2 trial in China by early 2027 for Sjögren's disease.
The Phase 2-ready program was supported by two Phase 1 healthy-volunteer studies and a completed Phase 1b study in Sjögren's disease, with no new safety signal reported.
